ViiV Healthcare

News

Merck halts more trials of HIV candidate islatravir

Merck & Co has halted enrolment in a pair of phase 3 trials of its experimental HIV drug islatravir, raising another warning flag about the highly-touted therapy.

News

NICE backs ViiV/J&J's six-per-year injection for HIV

People living with HIV in England and Wales now have an alternative to daily oral tablets, after NICE backed NHS use of two long-acting injectable therapies developed by ViiV Healthcare and

News

Gilead challenges ViiV in resistant HIV, filing twice-yearly...

Gilead Sciences has filed for FDA approval of a long-acting therapy for resistant HIV infections that only needs to be administered once every six months.

News

Pair of R&D updates bolster GSK ahead of investor meeting

GlaxoSmithKline (GSK) has reported encouraging data for its COVID-19 antibody sotrovimab, and an alliance with Halozyme to develop a new generation of long-acting HIV drugs, as it prepares

News

ViiV’s Rukobia cleared in EU as rescue HIV therapy

The European Commission has given a green light to the use of ViiV Healthcare’s Rukobia as a treatment for people with HIV that has developed resistance to other antiretroviral therapy (ART

News

ViiV launches digital triage service for HIV patients with L...

ViiV Healthcare and London’s Westminster Hospital NHS Foundation Trust have launched a digital triage service for HIV patients supported by a mobile app.

Merck halts more trials of HIV candidate islatravir

NICE backs ViiV/J&J's six-per-year injection for HIV

Gilead challenges ViiV in resistant HIV, filing twice-yearly...

Pair of R&D updates bolster GSK ahead of investor meeting

ViiV’s Rukobia cleared in EU as rescue HIV therapy

ViiV launches digital triage service for HIV patients with L...

CHMP decision levels the playing field for GSK's RSV jab

How to meet your physicians where they are online

ViiV Healthcare

Editor's Picks